Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fusilev sales boosts Spectrum, but analysts warn of fragility

This article was originally published in Scrip

Executive Summary

Spectrum Pharmaceuticals has reported increasing demand for its anticancer Fusilev (levolecovorin), and has increased its manufacturing capacity anticipating that the demand will "continue throughout 2012 and beyond". The company appears to be benefitting from a continuing generic leucovorin shortage. However, some analysts believe that uncertainties in the supply of generic leucovorin in the coming months could mean that Spectrum's revenue potential is fragile.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts